ArticleChemical science2018
Tetrazine-mediated bioorthogonal prodrug-prodrug activation.
Article in Chemical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Programmable nanomedicine via bioorthogonal molecular engineering.Nano convergence · 2026Review
- Rate-Tunable, Metal-Mediated Amide Bond Cleavage for the Controlled Release of Pharmaceuticals.Journal of the American Chemical Society · 2025Article
- Click-Triggered Bioorthogonal Bond-Cleavage Reactions.Topics in current chemistry (Cham) · 2025Review
- Prodrug activation by 4,4'-bipyridine-mediated aromatic nitro reduction.Nature communications · 2024Article
- A dual action coumarin-camptothecin polymer for light responsive drug release and photodynamic therapy.Polymer chemistry · 2024Article
- Article
- Metal-Mediated, Autolytic Amide Bond Cleavage: A Strategy for the Selective, Metal Complexation-Catalyzed, Controlled Release of Metallodrugs.Journal of the American Chemical Society · 2023Article
- Stereospecific Cu(I)-Catalyzed C-O Cross-Coupling Synthesis of Acyclic 1,2-Di- and Trisubstituted Vinylic Ethers from Alcohols and Vinylic Halides.Organic letters · 2023Article
- Solid-Phase Synthesis ofOrganic letters · 2023Article
- Targeted Molecular Construct for Bioorthogonal Theranostics of PD-L1-Expressing Cancer Cells.JACS Au · 2022Article
- Crystal structure of (Acta crystallographica. Section E, Crystallographic communications · 2022Article
- DNA-based platform for efficient and precisely targeted bioorthogonal catalysis in living systems.Nature communications · 2022Article
- Unleashing the Power of Bond Cleavage Chemistry in Living Systems.ACS central science · 2021Review
- Activation and Delivery of Tetrazine-Responsive Bioorthogonal Prodrugs.Molecules (Basel, Switzerland) · 2020Review
- Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.Chemical biology & drug design · 2020Article
- Coordinating bioorthogonal reactions with two tumor-microenvironment-responsive nanovehicles for spatiotemporally controlled prodrug activation.Chemical science · 2020Article
- Isonitrile-responsive and bioorthogonally removable tetrazine protecting groups.Chemical science · 2020Article
- "Close-to-Release": Spontaneous Bioorthogonal Uncaging Resulting from Ring-Closing Metathesis.Journal of the American Chemical Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The selective and biocompatible activation of prodrugs within complex biological systems remains a key challenge in medical chemistry and chemical biology. Herein we report, for the first time, a dual prodrug activation strategy that fully satisfies the principle of bioorthogonality by the symbiotic formation of two active drugs. This dual and traceless prodrug activation strategy takes advantage of the
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.